SGMT logo

SAGIMET BIOSCIENCES INC-A

SGMTNASDAQ
🏆 #3160 by market capEarnings Nov 12 · PreUS Equity
$10.75▲ $0.33 (+3.17%)
Pre-market · at close
🔔
Track SGMT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.2%
7d▲ 7.9%
14d▲ 31.4%
30d▲ 15.3%
ytd▲ 81.6%
1y▲ 29.0%
🏦Market Cap
$350M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$10.26 – $10.76
52-Week Range
$4.50 – $11.45
Volume (shares)
79,961
Avg Volume (shares)
—
Shares Outstanding
32.6M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-8.1
P/S Ratio
0.0x
EPS (TTM)
$-0.89
Dividend Yield
0.00%
Dilution (1yr)
+1.0%
SGMT logo

SAGIMET BIOSCIENCES INC-A

SGMT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$57M▲ +4.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$46M▲ +7.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
32.5M▲ +1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$35M▼ −$41M YoY
StockOtter · stockotter.space

About SAGIMET BIOSCIENCES INC-A

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
19 analysts
Strong Buy6
Buy11
Hold1
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.